Best Practice & Research Clinical Haematology
Volume 20, Issue 3 , Pages 385-397, September 2007

The normal counterpart to the chronic lymphocytic leukemia B cell

  • Federico Caligaris-Cappio, MD (Professor of Internal Medicine, Director of the Department of Oncology)

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +39 02 2643 2390; Fax: +39 02 2643 4723.
  • ,
  • Paolo Ghia, MD, PhD (Assistant Professor of Intenal Medicine, Scientific coordinator of the Lymphoma Unit)

Department of Oncology, Lymphoma Unit, Università Vita-Salute San Raffaele and Istituto Scientifico San Raffaele, Via Olgettina 58, 20132 Milano, Italy

Chronic lymphocytic leukemia (CLL) is characterized by the monoclonal expansion of small mature-looking B cells that accumulate in the blood, marrow, and lymphoid organs, and have a remarkable phenotypic homogeneity. By definition, CLL cells co-express CD5 and CD23 with faint to undetectable amounts of monoclonal surface immunoglobulins (sIg). The concept of phenotypic homogeneity has been reinforced by gene expression profiling data, which suggest that the pathogenesis of CLL has to be associated with a fairly common mechanism of transformation. In recent years the biology of CLL has been enriched by an unprecedented flurry of new observations that are leading to a better understanding of the natural history of the disease. Still CLL cells have so far defied any attempt to satisfactorily answer the simple time-honored question of what their cell of origin is. It is the purpose of this review to discuss the features a cell must possess to be considered with reasonable approximation the normal counterpart of a CLL B cell.

Key words: chronic lymphocytic leukemia, B lymphocytes, monoclonal B lymphocytosis, immunoglobulin

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S1521-6926(07)00021-7

doi:10.1016/j.beha.2007.02.005

Best Practice & Research Clinical Haematology
Volume 20, Issue 3 , Pages 385-397, September 2007